We are thrilled to be named by Endpoints News as a 2023 #endpts11 winner in recognition of our mission to harness enabling delivery technologies to develop transformative #geneticmedicines! Thank you to the Aera team for your unwavering commitment. endpts.com/the-endpoints-…

Idea: 2016 Company: 2018 NHP data: 2020 1st patient dosed: 2022 1st human data for in vivo liver base editing in patients with heterozygous familial hypercholesterolemia and ASCVD 👇🏽 American Heart Association Verve Therapeutics $VERV Stay tuned!

To build broad foundational models in biology, you are going to need a lot of high quality data. Aside from a few problems (e.g. protein folding), that data doesn't currently exist in the public domain. The winners of TechBio will have access to high quality talent, deep compute

Excited to announce DIMENSION's partnership with Mostafa elSayed and the Automata team! They are filling the crucial gap between experimental design and clean data output through a fully automated lab solution. Read more below: endpts.com/exclusive-auto…

Excited to see what my old team at Beam Therapeutics has been up to. They are some of the best in biotech.

Seems like you are learning a lot on your lab tour segments on @BiotechTVHQ Brad Loncar. I couldn’t agree more with this statement.

Thrilled to announce that U.S. FDA has cleared our *investigational new drug (IND)* application for VERVE-101 FDA reviewed our hold response which included: 1. interim clinical data from the ongoing heart-1 trial currently being conducted ex-U.S. 2. pre-clinical data to address

Congratulations to Verve on the open US IND for VERVE-101 — great news for the program and for the field:

1/ 🧠💻AI in Biopharma Case Study: Roche We will get more into this in the coming weeks in a Sunday newsletter. Sunday's are where we discuss topics related to emerging biopharma strategy. But follow this thread for some super cool real life use cases from Roche 🧵👇

Thank you to the legendary Steve Hartman for bringing Ara's song to a national audience!

💯 This is an under appreciated point. Running a lab like a factory (what we call a foundry at @ginkgo) is totally different culturally than a typical biotech. Took us years to get it right.

What if billions of dollars in #AI funding leads to the same number of new drugs? Today in STAT, Benchling co-founders Sajith and Ashutosh Singhal weigh in on how to avoid over-promising and under-delivering on AI-driven drug discovery. statnews.com/2024/06/25/ai-…

Check out this op-ed by Sajith and Ashutosh Singhal!

Our Lab Automation lead, Sam Mohler & Automation Engineer, Chris DeMaio head to the #SLAS conference to discuss the latest in #labautomation. Our digital & automated lab is a big part of what we've built at Aera, so we're excited to show our automated platform, Cosmos, in action.

Same story, 14 years and one day later. For the sake of patients, let’s hope for the same outcome! Keep going, CRISPR folk!

Wow. Boston Mayor, Michelle Wu, gave a fantastic speech at the House committee hearing on sanctuary cities. 🔥🔥🔥🔥🔥🔥🔥🔥

the most important tech of the next decade: A big compounding competitive advantage will go to companies—and countries🌎 that figure out how to use AI + automation🦾 + robots 🤖to do science 🔬🧪24 hrs a day to have runaway new knowledge production

Happy Sunday to all! This morning, we are excited to share Chase’s work developing a simple, scalable method to assemble 100s-1000s of custom genes from oligo pools using standard lab tools! (Small 🧵 below)

At 15, I left all my family and friends and came to the US , ALONE, seeking a country where MERIT and HARD WORK mattered-not politics. For 30 years, I worked tirelessly, even doing reseach at MIT the day my mother died, knowing she’d want me to keep pushing forward. Today, my

No words - only tears of joy. And bow of gratitude to Rebecca Ahrens-nicklas (CHOP) and Kiran Musunuru (Penn) and Sadik Kassim (Danaher) - our amazing partners in designing, derisking, and administering a CRISPR on demand to Baby KJ.